These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 33202931)

  • 1. Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
    Cives M; Pelle' E; Strosberg J
    J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33202931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs).
    Xu J
    Ther Adv Med Oncol; 2021; 13():17588359211042689. PubMed ID: 34484432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors.
    Das S; Dasari A
    Ther Adv Med Oncol; 2021; 13():17588359211018047. PubMed ID: 34093744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors.
    Dasari A; Hamilton EP; Falchook GS; Wang JS; Li D; Sung MW; Chien C; Nanda S; Tucci C; Hahka-Kemppinen M; Paulson AS
    Invest New Drugs; 2023 Jun; 41(3):421-430. PubMed ID: 37074571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine kinase inhibitors in patients with neuroendocrine neoplasms: a systematic literature review.
    Taboada RG; Cavalher FP; Rego JF; Riechelmann RP
    Ther Adv Med Oncol; 2024; 16():17588359241286751. PubMed ID: 39421680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Cancer Therapy: What's New in the Field of Neuroendocrine Neoplasms?
    La Salvia A; Espinosa-Olarte P; Riesco-Martinez MDC; Anton-Pascual B; Garcia-Carbonero R
    Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33916707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chinese multidisciplinary expert consensus on the rational use of surufatinib in clinical practice（2024 edition）].
    Chinese Multidisciplinary Expert Consensus on the Rational Use of Surufatinib in Clinical Practice-Editorial Board Group
    Zhonghua Zhong Liu Za Zhi; 2024 Oct; 46(10):930-939. PubMed ID: 39414593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial.
    Corti F; Brizzi MP; Amoroso V; Giuffrida D; Panzuto F; Campana D; Prinzi N; Milione M; Cascella T; Spreafico C; Randon G; Oldani S; Leporati R; Scotto G; Pulice I; Stocchetti BL; Porcu L; Coppa J; Di Bartolomeo M; de Braud F; Pusceddu S
    BMC Cancer; 2023 Sep; 23(1):908. PubMed ID: 37752423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surufatinib for the treatment of advanced extrapancreatic neuroendocrine tumors.
    Lu X; Yan S; Koral KA; Chen Z
    Expert Rev Anticancer Ther; 2021 Sep; 21(9):917-926. PubMed ID: 34142932
    [No Abstract]   [Full Text] [Related]  

  • 10. Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial.
    Xu J; Li J; Bai C; Xu N; Zhou Z; Li Z; Zhou C; Jia R; Lu M; Cheng Y; Mao C; Wang W; Cheng K; Su C; Hua Y; Qi C; Li J; Wang W; Li K; Sun Q; Ren Y; Su W
    Clin Cancer Res; 2019 Jun; 25(12):3486-3494. PubMed ID: 30833272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The State of Peptide Receptor Radionuclide Therapy and Its Sequencing among Current Therapeutic Options for Gastroenteropancreatic Neuroendocrine Tumors.
    Raymond LM; Korzun T; Kardosh A; Kolbeck KJ; Pommier R; Mittra ES
    Neuroendocrinology; 2021; 111(11):1086-1098. PubMed ID: 33744879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
    Fazio N; Cinieri S; Lorizzo K; Squadroni M; Orlando L; Spada F; Maiello E; Bodei L; Paganelli G; Delle Fave G; de Braud F
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S87-94. PubMed ID: 21129617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
    Harris PE; Zhernosekov K
    Front Endocrinol (Lausanne); 2022; 13():941832. PubMed ID: 36387893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics, clinical findings and approval status of current and emerging tyrosine-kinase inhibitors for pancreatic neuroendocrine tumors.
    Fazio N; Cella CA; Del Re M; Laffi A; Rubino M; Zagami P; Spada F
    Expert Opin Drug Metab Toxicol; 2019 Dec; 15(12):993-1004. PubMed ID: 31794273
    [No Abstract]   [Full Text] [Related]  

  • 15. Tyrosine Kinase Inhibitors and Immunotherapy Updates in Neuroendocrine Neoplasms.
    Mosalem O; Sonbol MB; Halfdanarson TR; Starr JS
    Best Pract Res Clin Endocrinol Metab; 2023 Sep; 37(5):101796. PubMed ID: 37414652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic treatment of neuroendocrine tumors with hepatic metastases.
    Demirkan BH; Eriksson B
    Turk J Gastroenterol; 2012; 23(5):427-37. PubMed ID: 23161287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide Receptor Radionuclide Therapy and the Treatment of Gastroentero-pancreatic Neuroendocrine Tumors: Current Findings and Future Perspectives.
    Hirmas N; Jadaan R; Al-Ibraheem A
    Nucl Med Mol Imaging; 2018 Jun; 52(3):190-199. PubMed ID: 29942397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiogenesis in NENs, with a focus on gastroenteropancreatic NENs: from biology to current and future therapeutic implications.
    Lauricella E; Mandriani B; Cavallo F; Pezzicoli G; Chaoul N; Porta C; Cives M
    Front Oncol; 2022; 12():957068. PubMed ID: 36059642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The predictive impact of dual somatostatin receptor/fluorodeoxyglucose (FDG) positron emission tomography (PET) in metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs): review of literature and a single institution experience.
    Mohamed A; Asa SL; Lee Z; Tirumani SH; Li Q; Avril N; Bajor D; Mahipal A; Chakrabarti S; Selfridge JE; Kardan A
    J Gastrointest Oncol; 2023 Apr; 14(2):1087-1094. PubMed ID: 37201086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
    Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.